Related Experiment Video
Updated: Mar 29, 2026

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
Effects of resveratrol on methotrexate-induced intestinal injury
Unlabelled:
Methotrexate (MTX) is an anticancer drug. Many studies have reported that MTX causes oxidative stress-associated damage in the small intestine. The purpose of this study was to investigate the possible protective effect of resveratrol (RES), an antioxidant, against MTX-induced damage in the small intestine.
Materials And Methods:
Twenty-four Spraque Dawley rats were randomly divided into four groups; the control group, the RES group given 20 mg/kg RES for 10 days, the MTX group given single dose 30 mg/kg MTX, MTX+RES group given 20 mg/kg RES i.p. for 7 days and 30 mg/ kg MTX i.p. on the 7th day, RES being maintained for 3 further days. All rats were sacrificed on the 10th day, and small intestinal tissue was removed for histopathological and biochemical analysis. Additionally, mucosal apoptosis was analyzed using the TUNEL method.
Results:
Histopathologically, villar fusion, atrophic villus epithelium, cystic expansion in crypts, hemorrhage and inflammatory cell infiltration were seen in the small intestine in the MTX group. In the MTX+RES group this histopathological damage decreased significantly. Apoptotic score was significantly higher in the MTX group and significantly lower in the MTX+RES group. Tissue malondialdehyde (MDA) level was significantly higher in the MTX group. Superoxide dismutase (SOD) activity was significantly decreased in the MTX group. The MDA level in the MTX+RES group decreased while SOD and catalase (CAT) activities rose, this was not statistically significant.
More Related Videos
07:05Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase